Fox Run Management, L.L.C. Uro Gen Pharma Ltd. Transaction History
Fox Run Management, L.L.C.
- $588 Million
- Q3 2025
A detailed history of Fox Run Management, L.L.C. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 16,902 shares of URGN stock, worth $411,225. This represents 0.06% of its overall portfolio holdings.
Number of Shares
16,902Holding current value
$411,225% of portfolio
0.06%Shares
2 transactions
Others Institutions Holding URGN
# of Institutions
171Shares Held
43.8MCall Options Held
1.61MPut Options Held
433K-
Rtw Investments, LP New York, NY4.54MShares$111 Million1.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.22MShares$103 Million2.65% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$77.6 Million0.1% of portfolio
-
Morgan Stanley New York, NY2.53MShares$61.5 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$53.5 Million0.21% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $553M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...